Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Actavis Will Acquire Rival Warner Chilcott

by Rick Mullin
May 27, 2013 | A version of this story appeared in Volume 91, Issue 21

Generic drug producer Actavis has agreed to acquire Dublin-based Warner Chilcott in a deal that the companies value at $8.5 billion, including debt. The acquisition will create a drugmaker with approximately $11 billion in annual revenues. It will also be the third-largest specialty pharmaceutical company in the U.S., with expertise in urology and women’s health. Actavis itself has been an acquisition target in recent months, with reports of bids for the firm being made by Valeant Pharmaceuticals and Mylan.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.